HCFA Proposes Cost As A Medicare Coverage Criteria If Alternatives Exist
Executive Summary
The Health Care Financing Administration would consider cost in deciding whether Medicare should cover a medical technology that employs the same "clinical modality" as an alternative treatment used for the same indication and already covered by Medicare.
You may also be interested in...
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
The Centers for Medicare & Medicaid Services' "functionally equivalent" determination for Aranesp versus Procrit may be a useful model for value-based purchasing by Medicare in the future, a report by the Medicare Payments Advisory Commission suggests
HCFA Cost Considerations In Proposed Drug Coverage Criteria To Be Revised
The Health Care Financing Administration plans to eliminate or significantly scale back the role of cost in its proposed criteria for making Medicare drug coverage decisions, the agency indicated after receiving comments on its May 16 notice of intent to publish a proposed rule.